Esogas-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms associated with functional dyspepsia, gastroesophageal reflux disease (GERD), and delayed gastric emptying. Esomeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing symptomatic relief and promoting mucosal healing in acid-related conditions such as GERD, erosive esophagitis, and peptic ulcers. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and clinical efficacy. Esogas-L Capsule SR is indicated for patients presenting with combined motility and acid-related gastrointestinal disorders requiring both acid suppression and prokinetic therapy. Caution is advised in patients with hypersensitivity to either component, and it should be used under medical supervision, particularly in those with hepatic or renal impairment. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. This combination therapy offers a synergistic approach to managing complex gastrointestinal symptoms, improving patient quality of life.